First-in-Human trial launches for targeted radiation therapy against FAP-Expressing tumors
NCT ID NCT07681141
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a new radioactive drug called 177Lu-JH040182 in people with advanced cancers that have a protein called FAP on their cells. The drug is designed to deliver radiation directly to the tumor. The main goals are to check safety and measure how much radiation reaches the tumors and healthy organs. Only three people will take part, making this an early step in exploring whether this treatment could be developed further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-JH040182 (a radioactive drug that targets FAP on tumor cells)
- What this could lead to
- If safe and effective, this approach could offer a new treatment option for patients with advanced cancers that express FAP.
- What could go wrong
- This is a very early, small study (3 people) focused on safety and dosing, not on curing the cancer. The drug may cause side effects or not shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, 350005, China